52 Week High: $160.33
52 Week Low: $12.6
50 Day MA: $18.27
200 Day MA: $15.49
Low: $12.6
High: $160.33
Low: $158.52
High: $162.22
As of November 2023, Novo Nordisk (NVO) has a market cap of $356.4 billion. Our data points out that NVO is ranked #22 in the world. A company's market capitalization is the present value of all of its outstanding shares, and it is commonly used to give a sense of how much the stock of a company would be worth at today's exchange rates. NVO's market cap is -4.43763% down from the last trading day.
Address: Novo Allé 1
City: Bagsvaerd
Zip: 2880
Phone: 45 44 44 88 88
Website: https://www.novonordisk.com
IPO Date: 1982-01-04
CEO: Lars Fruergaard Jorgensen
Employees: 50,816
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
